COR|Analyst Targets
COR|Company Info
COR|Insider Trading
COR|Fundamentals
COR|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $4.57 | - | - |
| Q3'26 | $4.39 | $4.48 | +2.0% |
| Q2'26 | $4.33 | $4.75 | +9.6% |
| Q3'25 | $3.79 | $3.84 | +1.4% |
| Q2'25 | $3.84 | $4.00 | +4.2% |
| Q1'25 | $4.10 | $4.42 | +7.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'26 | $88.9B | - | - |
| Q3'26 | $85.2B | $84.8B | -0.5% |
| Q2'26 | $87.2B | $78.4B | -10.2% |
| Q3'25 | - | $83.7B | - |
| Q2'25 | - | $80.7B | - |
| Q1'25 | - | $75.5B | - |
COR|Monthly Returns
Market Data
COR Stock Snapshot
- Market cap
- 62.19B
- P/E ratio
- 23.7
- Day range
- $330.29 – $330.29
- News sentiment
- 57/100 · Neutral
- Analyst target
- $369.92 (+12.0%)
- Consensus
- Buy · 23 analysts
COR sits in the middle of its 52-week range with the technical picture unresolved. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.
Reverse DCF
What growth is priced into COR?
At today's price, Cencora, Inc. needs to grow free cash flow about -1.7% a year for the next 10 years to justify its valuation at a 6.55% cost of capital. Over its actual history it has compounded free cash flow at 8.7% a year, so the market is asking for 10.4 percentage points below its own delivered rate. On that basis COR looks priced below what its own growth record supports.
- Implied FCF growth
- -1.7%
- Historical FCF CAGR
- 8.7%
- Growth gap
- -10.4 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 6.55%
- Beta
- 0.31
Behaviour On Record
What COR's own history says about today's numbers
- Realized volatility (21d)
- 24.1% 65th pct
- Below its peak
- -13.6%
- vs 200-day average
- +2.0%
- Up days (1y)
- 53%
Cencora, Inc. is currently running 24.1% annualised volatility over the last 21 sessions. Measured against COR's own 13 years of daily returns rather than a market-wide average, that is the 65th percentile — a little above its own norm, against a typical reading of 21.2%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
COR is trading -13.6% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -18.3%, and the deepest was -33.0% in 2016. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +2.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 35th percentile — close to the gap it normally carries. Over the past year COR closed higher on 53% of sessions, and it is currently 2 sessions into a rising streak.
On October specifically: over 13 years of records, COR finished the month higher 9 of 13 times, with a median return of +2.1% and an average of +1.8%. Its strongest month historically has been November at +4.8% on average, its weakest August at -1.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: COR has opened more than 2% away from the prior close in 91 of 3,266 sessions (2.8% of the time), with the largest gaps running +6.6% and -11.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against COR's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of COR's sector?
Cencora, Inc. sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #5 of 12
- Sector state
- Improving
- Sector rotation score
- 64
Analyst Rating Changes
Are analysts turning bullish or bearish on COR?
Leerink Partners most recently reiterated its rating on Cencora, Inc. to Outperform on Oct 7, 2026 with a price target of $388 (from $380). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Leerink Partners — Outperform
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Peers & ETF holders
COR peers & ETF holders
Medical DistributionMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 23,617,117 | 12.54% | $7.98B | 2026-01-29 |
| BlackRock, Inc. | ▼ Sell | 18,213,783 | 9.67% | $5.15B | 2026-08-07 |
| JPMorgan Chase & Co | ▲ Buy | 5,943,657 | 3.16% | $1.67B | 2026-08-12 |
| Geode Capital Management, LLC | ▼ Sell | 5,454,888 | 2.90% | $1.54B | 2026-08-12 |
| Wellington Management Group LLP | ▲ Buy | 4,559,761 | 2.42% | $1.29B | 2026-08-14 |
| FMR LLC (Fidelity) | ▼ Sell | 4,122,371 | 2.19% | $1.17B | 2026-08-13 |
| Morgan Stanley | ▼ Sell | 4,086,271 | 2.17% | $1.16B | 2026-08-13 |
| Bank of America Corp | ▼ Sell | 3,733,921 | 1.98% | $1.06B | 2026-08-14 |
| Norges Bank | ▲ Buy | 2,473,825 | 1.31% | $700.04M | 2026-08-12 |
| Goldman Sachs Group Inc | ▲ Buy | 2,274,148 | 1.21% | $643.54M | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 2,158,939 | 1.15% | $610.94M | 2026-08-13 |
| Invesco Ltd. | ▼ Sell | 2,021,234 | 1.07% | $571.97M | 2026-08-14 |
| Capital Research Global Investors | ▲ Buy | 1,979,942 | 1.05% | $560.28M | 2026-08-12 |
| Citadel Advisors LLC | ▲ Buy | 1,366,647 | 0.73% | $386.73M | 2026-09-02 |
| Wells Fargo & Company | ▼ Sell | 1,285,421 | 0.68% | $363.75M | 2026-08-14 |
| Neuberger Berman Group LLC | ▲ Buy | 1,174,269 | 0.62% | $332.18M | 2026-08-13 |
| Millennium Management LLC | ▲ Buy | 950,479 | 0.50% | $268.97M | 2026-08-14 |
| AllianceBernstein L.P. | ▼ Sell | 653,472 | 0.35% | $205.28M | 2026-08-14 |
| Balyasny Asset Management L.P. | ▲ Buy | 608,612 | 0.32% | $172.23M | 2026-08-14 |
| Point72 Asset Management, L.P. | ▲ Buy | 604,746 | 0.32% | $171.13M | 2026-08-14 |
| Squarepoint Ops LLC | ▲ Buy | 544,295 | 0.29% | $154.02M | 2026-08-14 |
| Janus Henderson Group plc | ▼ Sell | 389,542 | 0.21% | $122.37M | 2026-05-18 |
| Marshall Wace, LLP | ▲ Buy | 342,176 | 0.18% | $96.83M | 2026-08-13 |
| Citigroup Inc | ▼ Sell | 279,904 | 0.15% | $79.21M | 2026-08-03 |
| AQR Capital Management LLC | ▼ Sell | 272,728 | 0.14% | $76.38M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Jared Moskowitz | House | FL23 | ▼ Sell | $1K - $15K | 2026-05-06 | 2026-06-19 |
| Jared Moskowitz | House | FL23 | ▲ Buy | $1K - $15K | 2026-03-31 | 2026-04-30 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Jared Moskowitz | House | FL23 | ▲ Buy | $1K - $15K | 2026-03-23 | 2026-04-30 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $50K - $100K | 2025-05-12 | 2025-06-22 |
| Greg Landsman | House | OH01 | ▼ Sell | $15K - $50K | 2025-03-27 | 2025-04-08 |